Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed - Concepedia

Concepedia

Publication | Open Access

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed

DOI Full Paper Access

279

Citations

43

References

2015

Year

Herbert I. Hurwitz, Nikhil Uppal, Stephanie A. Wagner, Johanna C. Bendell, J. Thaddeus Beck, Seaborn M. Wade, John Nemunaitis, Philip J. Stella, J. Marc Pipas, Zev A. Wainberg,

Journal of Clinical Oncology

Abstract

Ruxolitinib plus capecitabine was generally well tolerated and may improve survival in patients with metastatic pancreatic cancer and evidence of systemic inflammation.

References

	Year	Citations

Page 1